[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649302":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":28,"centralContacts":35,"locations":43,"responsibleParty":202,"collaborators":28,"id":204,"slug":205,"hasResults":206,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":28,"eligibilityCriteria":210,"healthyVolunteers":206,"sex":211,"minAge":212,"maxAge":213,"enrollmentInfo":214,"targetDuration":28,"studyType":217,"phases":218,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":46,"whyStopped":28,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},{"fullName":5,"class":6},"Leal Therapeutics, Inc","INDUSTRY",[8,13,19],{"label":9,"type":10,"description":9,"interventionNames":11},"Placebo","PLACEBO_COMPARATOR",[12],"Drug: Placebo",{"label":14,"type":15,"description":16,"interventionNames":17},"LTX-001 once daily","EXPERIMENTAL","LTX-001",[18],"Drug: LTX-001 once daily",{"label":20,"type":15,"description":16,"interventionNames":21},"LTX-001 twice daily",[22],"Drug: LTX-001 twice daily",[24,29,32],{"type":25,"name":14,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","LTX-001 40 mg and 60 mg administered as oral suspension",[14],null,{"type":25,"name":9,"description":30,"armGroupLabels":31,"otherNames":28},"Oral suspension without LTX-001",[9],{"type":25,"name":20,"description":33,"armGroupLabels":34,"otherNames":28},"LTX-001 30 mg and 60 mg administered as oral suspension",[20],[36,41],{"name":37,"role":38,"phone":39,"phoneExt":28,"email":40},"Clinical Trials Information Medical Monitor","CONTACT","267-503-4800","clinical.trials@lealtx.com",{"name":42,"role":38,"phone":28,"phoneExt":28,"email":28},"Study Director Medical Monitor",[44,65,81,98,113,125,138,154,170,187],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Pillar Clinical Research, LLC","RECRUITING","Little Rock","Arkansas","72204","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-92.28959,34.74648,{"lat":56,"lon":55},[59,62],{"name":60,"role":38,"phone":28,"phoneExt":28,"email":61},"Leslie Smith","Studies@pillarhc.com",{"name":63,"role":64,"phone":28,"phoneExt":28,"email":28},"Leslie Smith, MD","PRINCIPAL_INVESTIGATOR",{"facility":66,"status":46,"city":67,"state":68,"zip":69,"country":50,"countryCode":51,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Collaborative Neuroscience Research, LLC","Los Alamitos","California","90720",{"type":53,"coordinates":71},[72,73],-118.07256,33.80307,{"lat":73,"lon":72},[76,79],{"name":77,"role":38,"phone":78,"phoneExt":28,"email":28},"Study Recruiter","(714)-891-0971",{"name":80,"role":64,"phone":28,"phoneExt":28,"email":28},"David Walling, PhD",{"facility":82,"status":83,"city":84,"state":85,"zip":86,"country":50,"countryCode":51,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"University Clinical Research-DeLand, LLC d\u002Fb\u002Fa Accel Research Sites - DeLand Clinical Research Unit","NOT_YET_RECRUITING","DeLand","Florida","32720",{"type":53,"coordinates":88},[89,90],-81.30312,29.02832,{"lat":90,"lon":89},[93,96],{"name":94,"role":38,"phone":28,"phoneExt":28,"email":95},"Bruce Rankin","bruce.rankin@accelclinical.com",{"name":97,"role":64,"phone":28,"phoneExt":28,"email":28},"Bruce Rankin, MD",{"facility":99,"status":46,"city":100,"state":85,"zip":101,"country":50,"countryCode":51,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Behavioral Clinical Research, Inc.","Hollywood","33021",{"type":53,"coordinates":103},[104,105],-80.14949,26.0112,{"lat":105,"lon":104},[108,111],{"name":109,"role":38,"phone":28,"phoneExt":28,"email":110},"Leandro Rueda","lrueda@segaltrials.com",{"name":112,"role":64,"phone":28,"phoneExt":28,"email":28},"Olga Lapeyra, MD",{"facility":114,"status":46,"city":100,"state":85,"zip":115,"country":50,"countryCode":51,"cosmosGeoPoint":116,"geoPoint":118,"contacts":119},"CenExel Hollywood FL","33024",{"type":53,"coordinates":117},[104,105],{"lat":105,"lon":104},[120,123],{"name":121,"role":38,"phone":122,"phoneExt":28,"email":28},"Edwin A Gomez","954-990-7649",{"name":124,"role":64,"phone":28,"phoneExt":28,"email":28},"Edwin A Gomez, MD",{"facility":126,"status":46,"city":127,"state":85,"zip":128,"country":50,"countryCode":51,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"Innovative Clinical Research, Inc.","Miami Lakes","33016",{"type":53,"coordinates":130},[131,132],-80.30866,25.90871,{"lat":132,"lon":131},[135,136],{"name":109,"role":38,"phone":28,"phoneExt":28,"email":110},{"name":137,"role":64,"phone":28,"phoneExt":28,"email":28},"Rishi Kakar, MD",{"facility":139,"status":46,"city":140,"state":141,"zip":142,"country":50,"countryCode":51,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"CenExel iResearch, LLC","Decatur","Georgia","30030",{"type":53,"coordinates":144},[145,146],-84.29631,33.77483,{"lat":146,"lon":145},[149,152],{"name":150,"role":38,"phone":28,"phoneExt":28,"email":151},"Michael Mahaffey","m.mahaffey@cenexel.com",{"name":153,"role":64,"phone":28,"phoneExt":28,"email":28},"Kimball Johnson, MD",{"facility":155,"status":46,"city":156,"state":157,"zip":158,"country":50,"countryCode":51,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"CBH Health LLC., dba CenExel Gaithersburg MD","Gaithersburg","Maryland","20877",{"type":53,"coordinates":160},[161,162],-77.20137,39.14344,{"lat":162,"lon":161},[165,168],{"name":166,"role":38,"phone":167,"phoneExt":28,"email":28},"Elia Acevedo-Diaz","301-251-4702",{"name":169,"role":64,"phone":28,"phoneExt":28,"email":28},"Elia Acevedo-Diaz, MD",{"facility":171,"status":46,"city":172,"state":173,"zip":174,"country":50,"countryCode":51,"cosmosGeoPoint":175,"geoPoint":179,"contacts":180},"Hassman Research Institute, LLC","Marlton","New Jersey","08053",{"type":53,"coordinates":176},[177,178],-74.92183,39.89122,{"lat":178,"lon":177},[181,185],{"name":182,"role":38,"phone":183,"phoneExt":28,"email":184},"Lisa Wilkins","888-437-4104","L.Wilkins@CenExel.com",{"name":186,"role":64,"phone":28,"phoneExt":28,"email":28},"Elan Cohen, MD",{"facility":45,"status":46,"city":188,"state":189,"zip":190,"country":50,"countryCode":51,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"Richardson","Texas","75080",{"type":53,"coordinates":192},[193,194],-96.72972,32.94818,{"lat":194,"lon":193},[197,200],{"name":198,"role":38,"phone":28,"phoneExt":28,"email":199},"Scott Bartley","studies@pillarhc.com",{"name":201,"role":64,"phone":28,"phoneExt":28,"email":28},"Scott Bartley, MD",{"type":203,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100649302","phase-1-a-study-of-ltx-001-in-adult-participants-with-acute-exacerbation-of-schizophrenia-100649302",false,"NCT07734493","A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia","A Phase 1b, Multicenter, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Early Signs of Efficacy of Orally Administered LTX-001 As Monotherapy in Adult Participants With Acute Exacerbation of Schizophrenia","Inclusion Criteria:\n\n* BMI \\> 17.5 and \\\u003C 38.0 kg\u002Fm2 and a total body weight \\> 50.0 kg (110 lbs)\n* Primary diagnosis of schizophrenia per the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5-TR)\n* Experiencing an acute exacerbation or relapse of symptoms, with onset less than 2 months prior to screening for the study\n* PANSS total score ≥ 80 at the time of screening for the study\n* Not currently on antipsychotic medication, or is willing to discontinue all prohibited psychotropic medications prior to and during the trial period\n* Sexually active adults must be willing to use an acceptable contraceptive method throughout the study\n\nExclusion Criteria:\n\n* Evidence of organ dysfunction or any clinically significant abnormal finding at physical examination\n* History of treatment resistance (e.g., failure to respond to ≥ 2 adequate antipsychotic trials) or failure to respond to use of clozapine\n* Current DSM-5-TR diagnosis other than schizophrenia\n* Pregnant or lactating female\n* Substance use disorder within 1 year prior to screening or recreational use of drugs within 3 months prior to screening\n* Moderate to severe alcohol use disorder as per DSM-5-TR within the past year or excessive use of alcohol within 12 months prior to screening\n* Positive testing for human immunodeficiency virus (HIV)-1 and -2 antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening","ALL","18 Years","55 Years",{"count":215,"type":216},90,"ESTIMATED","INTERVENTIONAL",[219],"PHASE1","The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are:\n\n* how does the amount of the study drug in the body change over time (pharmacokinetics)\n* how does the study drug affect the symptoms of schizophrenia\n* how do certain markers in the blood change after administration of LTX-001 (pharmacodynamics)\n\nResearchers will compare different dose levels of LTX-001 to an inactive product (placebo) to see what differences there are between the two treatments.\n\nAfter successfully screening for the study, participants will stay in a research unit for about five weeks and return one week later for a follow-up visit.",[222],"Schizophrenia",[224],"schizophrenia","2026-08-19",{"date":227,"type":228},"2026-08-21","ACTUAL",{"date":230,"type":216},"2026-08",{"date":232,"type":216},"2027-03",{"name":5,"class":6},10]